CAR T cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,545

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,539

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges

Xiao, B., Zhang, J., Zhu, Y., Cui, X., Lu, Z., Yu, B., & Wu, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782775 · Cited by 57

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance

Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 56

Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy

Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 54

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

Yu, M., Yang, W., Yue, W., & Chen, Y. (2022) · Advanced Science · doi:10.1002/advs.202204335 · Cited by 54

Innovation in Chemistry, Manufacturing, and Controls—A Regulatory Perspective From Industry

Cauchon, N. S., Oghamian, S., Hassanpour, S., & Abernathy, M. J. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.02.007 · Cited by 59

Therapeutic Strategies for Targeting IL-1 in Cancer

Gottschlich, A., Endres, S., & Kobold, S. (2021) · Cancers · doi:10.3390/cancers13030477 · Cited by 58

Advances in Engineering Cells for Cancer Immunotherapy

Xu, X., Li, T., Shen, S., Wang, J., Abdou, P., Gu, Z., & Mo, R. (2019) · Theranostics · doi:10.7150/thno.38583 · Cited by 53

PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer

Gray, K. D., McCloskey, J. E., Vedvyas, Y., Kalloo, O. R., Eshaky, S. E., Yang, Y., Shevlin, E., Zaman, M., Ullmann, T. M., Liang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1523 · Cited by 53

CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer

Włodarczyk, M., & Pyrzyńska, B. (2022) · Cancers · doi:10.3390/cancers15010117 · Cited by 54

CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope

Hopfinger, G., Jaeger, U., & Worel, N. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000185 · Cited by 56

Leveraging machine vision in cell-based diagnostics to do more with less

Doan, M., & Carpenter, A. E. (2019) · Nature Materials · doi:10.1038/s41563-019-0339-y · Cited by 55

Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia

Jain, T., & Litzow, M. R. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620719899897 · Cited by 55

CAR-T cell therapy for lung cancer: a promising but challenging future

Zhong, S., Cui, Y., Liu, Q., & Chen, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.118 · Cited by 53

Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy

Gavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 53

T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy

Calvo, V., & Izquierdo, M. (2022) · Cells · doi:10.3390/cells11050790 · Cited by 56

Targeting strategies for mRNA delivery

Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55

Massively parallel knock-in engineering of human T cells

Dai, X., Park, J. J.-Y., Du, Y., Na, Z., Lam, S. Z., Chow, R. D.-W., Renauer, P. A., Gu, J., Shan, X., Chu, Z., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01639-x · Cited by 56

The CD47-SIRPα axis is a promising target for cancer immunotherapies

Hao, Y., Zhou, X., Li, Y., Li, B., & Lei, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110255 · Cited by 54

Biomaterials as Tools to Decode Immunity

Eppler, H. B., & Jewell, C. M. (2019) · Advanced Materials · doi:10.1002/adma.201903367 · Cited by 53

Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR

Lou, Y., Chen, C., Long, X., Gu, J., Xiao, M., Wang, D., Zhou, X., Li, T., Hong, Z., Li, C., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.02.007 · Cited by 55

Rewiring Mitochondrial Metabolism for CD8+ T Cell Memory Formation and Effective Cancer Immunotherapy

Li, W., & Zhang, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01834 · Cited by 54

Heterodimeric IL-15 in Cancer Immunotherapy

Bergamaschi, C., Stravokefalou, V., Stellas, D., Karaliota, S., Felber, B. K., & Pavlakis, G. N. (2021) · Cancers · doi:10.3390/cancers13040837 · Cited by 53

Cancer-Associated Fibroblasts: Implications for Cancer Therapy

Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 58

Cardiovascular toxicity of immune therapies for cancer

Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 61

The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies

Hu, M., Deng, F., Song, X., Zhao, H., & Yan, F. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03115-7 · Cited by 57

Leveraging the Photofunctions of Transition Metal Complexes for the Design of Innovative Phototherapeutics

Lee, L. C., & Lo, K. K. (2024) · Small Methods · doi:10.1002/smtd.202400563 · Cited by 52

High Throughput and Highly Controllable Methods for In Vitro Intracellular Delivery

Brooks, J. R., Minnick, G., Mukherjee, P., Jaberi, A., Chang, L., Espinosa, H. D., & Yang, R. (2020) · Small · doi:10.1002/smll.202004917 · Cited by 51

Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy

Wang, T., Shen, Y., Luyten, S., Yang, Y., & Jiang, X. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104876 · Cited by 53

CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing

Hossain, M. A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.001 · Cited by 57

Delivery strategies in treatments of leukemia

Ci, T., Zhang, W., Qiao, Y., Li, H., Zang, J., Li, H., Feng, N., & Gu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00755f · Cited by 50

T cell-derived exosomes in tumor immune modulation and immunotherapy

Zhou, Q., Wei, S., Wang, H., Li, Y., Fan, S., Cao, Y., & Wang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130033 · Cited by 51

Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine‐19 MRI detection

Hingorani, D. V., Chapelin, F., Stares, E., Adams, S., Okada, H., & Ahrens, E. T. (2019) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27988 · Cited by 51

Fatty Acid Metabolism and Cancer Immunotherapy

Luo, Y., Wang, H., Liu, B., & Wei, J. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01223-1 · Cited by 53

Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer

Kennedy, P. R., Felices, M., & Miller, J. S. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02769-4 · Cited by 50

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy

Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 54

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy

Pagotto, S., Simeone, P., Brocco, D., Catitti, G., Bellis, D. D., Vespa, S., Pietro, N. D., Marinelli, L., Stefano, A. D., Veschi, S., et al. (2023) · Cancers · doi:10.3390/cancers15041052 · Cited by 53

γ-Glutamyl transpeptidase-activable nanoprobe crosses the blood-brain barrier for immuno-sonodynamic therapy of glioma

Li, B., Chen, G., Zhong, H., Li, T., Lin, M., Wei, H., Zhang, Q., Chen, Q., Huang, J., & Shuai, X. (2024) · Nature Communications · doi:10.1038/s41467-024-54382-z · Cited by 52

Clinical applications of CRISPR‐based genome editing and diagnostics

Foss, D. V., Hochstrasser, M. L., & Wilson, R. C. (2019) · Transfusion · doi:10.1111/trf.15126 · Cited by 51

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells

Darowski, D., Kobold, S., Jöst, C., & Klein, C. (2019) · mAbs · doi:10.1080/19420862.2019.1596511 · Cited by 50

A Universal Platform for High‐Efficiency “Engineering” Living Cells: Integration of Cell Capture, Intracellular Delivery of Biomolecules, and Cell Harvesting Functions

Qu, Y., Zheng, Y., Yu, L., Zhou, Y., Wang, Y., Zhang, Y., Yu, Q., & Chen, H. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906362 · Cited by 50

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

Chruściel, E., Urban‐Wójciuk, Z., Arcimowicz, Ł., Kurkowiak, M., Kowalski, J., Gliwiński, M., Marjański, T., Rzyman, W., Biernat, W., Dziadziuszko, R., et al. (2020) · Cancers · doi:10.3390/cancers12030683 · Cited by 53

How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy

Li, J., & Stanger, B. Z. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1420 · Cited by 54

The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS

Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.032 · Cited by 50

The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling

Alame, M., Cornillot, E., Cacheux, V., Rigau, V., Costes‐Martineau, V., Szablewski, V., & Colinge, J. (2021) · Theranostics · doi:10.7150/thno.54343 · Cited by 51

The Cross Talk between Cancer Stem Cells/Cancer Initiating Cells and Tumor Microenvironment: The Missing Piece of the Puzzle for the Efficient Targeting of these Cells with Immunotherapy

Ravindran, S., Rasool, S., & Maccalli, C. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00233-1 · Cited by 49

Shaping of T Cell Functions by Trogocytosis

NAKAYAMA, M., Hori, A., Toyoura, S., & Yamaguchi, S.-I. (2021) · Cells · doi:10.3390/cells10051155 · Cited by 55

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Meng, J., Wu, X., Sun, Z., Xun, R., Liu, M., Hu, R., & Huang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698607 · Cited by 48

Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol

Yang, L., Yin, J., Wu, J., Qiao, L., Zhao, E. M., Cai, F., & Ye, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106612118 · Cited by 50

Recent progresses of exosome–liposome fusions in drug delivery

Zheng, L., Hu, B., Zhao, D., Liu, W., Liu, Q., Huang, Y., & Ruan, S. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108647 · Cited by 50

Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells

Meng, F., Zhang, S., Xie, J., Zhou, Y., Wu, Q., Lu, B., Zhou, S., Zhao, X., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01455-z · Cited by 53

Mapping pediatric brain tumors to their origins in the developing cerebellum

Okonechnikov, K., Joshi, P. K., Sepp, M., Leiss, K., Sarropoulos, I., Murat, F., Sill, M., Beck, P., Chan, K. C.-H., Korshunov, A., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad124 · Cited by 52

Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy

Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 51

Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer

Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 49

Nano/genetically engineered cells for immunotherapy

Shen, J., Zhou, Y., & Yin, L. (2024) · BMEMat · doi:10.1002/bmm2.12112 · Cited by 50

Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy

Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y., & Nagano, H. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12180 · Cited by 50

Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer

Wang, H., Wang, S., Huang, M.-C., Liang, X., Tang, Y.-J., & Tang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00498 · Cited by 55

DDR1 promotes breast tumor growth by suppressing antitumor immunity

Zhong, X., Zhang, W., & Sun, T. (2019) · Oncology Reports · doi:10.3892/or.2019.7338 · Cited by 49

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Cao, W., Wei, J., Wang, N., Xu, H., Xiao, M., Huang, L., Cao, Y., Li, C., Xiao, Y., Gu, C., et al. (2020) · Blood · doi:10.1182/blood.2020004907 · Cited by 48

Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy

Hardman, C., Ho, S., Shimizu, A., Luu-Nguyen, Q. H., Sloane, J. L., Soliman, M. S. A., Marsden, M. D., Zack, J. A., & Wender, P. A. (2020) · Nature Communications · doi:10.1038/s41467-020-15742-7 · Cited by 49

Immunotherapy for Medulloblastoma: Current Perspectives

Kabir, T., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s198162 · Cited by 51

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells

Phanthaphol, N., Somboonpatarakun, C., Suwanchiwasiri, K., Chieochansin, T., Sujjitjoon, J., Wongkham, S., Maher, J. F., Junking, M., & Yenchitsomanus, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.657868 · Cited by 49

Single-cell sorting based on secreted products for functionally defined cell therapies

Miwa, H., Dimatteo, R., de Rutte, J. M., Ghosh, R., & Carlo, D. D. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00422-x · Cited by 50

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

Seifert, M., Benmebarek, M.-R., Briukhovetska, D., Märkl, F., Dörr, J., Cadilha, B. L., Jobst, J., Stock, S., Andreu-Sanz, D., Lorenzini, T., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02013-z · Cited by 51

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model

Liu, W. N., So, W. Y., Harden, S. L., Fong, S. Y., Wong, M. X. Y., Tan, W. W. S., Tan, S. Y., Ong, J. K. L., Rajarethinam, R., Liu, M., et al. (2022) · Science Advances · doi:10.1126/sciadv.add1187 · Cited by 52

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges

Golikova, E., Alshevskaya, A., Alrhmoun, S., Sivitskaya, N. A., & Sennikov, S. V. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05703-9 · Cited by 50

CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells

Wang, L., Wang, Y., He, X., Mo, Z., Zhao, M., Liang, X., Hu, K., Wang, K., Yue, Y., Mo, G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101889 · Cited by 48

T cell immunotherapy enhanced by designer biomaterials

Dunn, Z. S., Mac, J., & Wang, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119265 · Cited by 48

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 47

Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies

Watanabe, K., & Nishikawa, H. (2021) · International Immunology · doi:10.1093/intimm/dxab052 · Cited by 50

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

van Diest, E., Hernández-López, P., Meringa, A. D., Vyborova, A., Karaiskaki, F., Heijhuurs, S., Bormin, J. G., van Dooremalen, S., Nicolasen, M. J. T., Gatti, L. C. D. E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003850 · Cited by 49

Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis

Dizman, G. T., Aguado, J. M., & Fernández‐Ruiz, M. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2128762 · Cited by 47

Recent advances in CAR-T cells therapy for colorectal cancer

Qin, X., Wu, F., Chen, C., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904137 · Cited by 47

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma

Yang, J., Zhou, W., Li, D., Niu, T., & Wang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215949 · Cited by 51

Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma

Shi, X., Dong, A., Jia, X., Zheng, G., Wang, N., Wang, Y., Yang, C., Lü, J., & Yang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992990 · Cited by 48

Biomaterials-Mediated Engineering of the Immune System

Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 52

mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

Olivera, I., Bolaños, E., González-Gomariz, J., Hervás‐Stubbs, S., Mariño, K. V., Luri‐Rey, C., Etxeberría, I., Cirella, A., Egea, J., Glez‐Vaz, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100978 · Cited by 46

T cell immunotherapy for cervical cancer: challenges and opportunities

Yu, L., Lanqing, G., Huang, Z., Xin, X., Liang, M., Fa-hui, L., Zou, H., & Min, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105265 · Cited by 51

Natural Killer Cells: A Review of Biology, Therapeutic Potential and Challenges in Treatment of Solid Tumors

Choucair, K., Duff, J. R., Cassidy, C. S., Albrethsen, M., Kelso, J. D., Lenhard, A., Staats, H., Patel, R., Brunicardi, F. C., Dworkin, L. D., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0116 · Cited by 49

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

Bôle‐Richard, E., Fredon, M., Biichlé, S., Anna, F., Certoux, J.-M., Renosi, F., Tsé, F., Molimard, C., Valmary‐Degano, S., Jenvrin, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0777-1 · Cited by 52

B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma

Long, C., Li, G., Zhang, C., Jiang, T., Li, Y., Duan, X., & Zhong, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659662 · Cited by 47

Nano-drug delivery systems for T cell-based immunotherapy

Li, R. P., Chen, Z., Li, J., Dai, Z., & Yu, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101621 · Cited by 48

CAR Macrophages for SARS-CoV-2 Immunotherapy

Fu, W., Lei, C., Qian, K., Ma, Z., Tian, L., Lin, F., Zhang, W., Zhao, J., & Hu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669103 · Cited by 47

Magnesium alloys in tumor treatment: Current research status, challenges and future prospects

Hsu, Y., Lu, Y., Wang, S., Zheng, Y., Xia, D., & Liu, Y. (2023) · Journal of Magnesium and Alloys · doi:10.1016/j.jma.2023.08.008 · Cited by 47

The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies

Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48

Neuroblastoma: an ongoing cold front for cancer immunotherapy

Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N., & Woolley, J. F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007798 · Cited by 52

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor

Liao, Z., Jiang, J., Wu, W., Shi, J., Wang, Y., Yao, Y., Sheng, T., Liu, F., Liu, W., Zhao, P., et al. (2024) · National Science Review · doi:10.1093/nsr/nwae018 · Cited by 48

Immune surveillance of senescence: potential application to age-related diseases

Wang, T., & Nakanishi, M. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.06.007 · Cited by 49

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy

Frisch, A. T., Wang, Y., Xie, B., Yang, A., Ford, B. R., Joshi, S. K., Kedziora, K. M., Peralta, R. M., Wilfahrt, D. N., Mullett, S. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.007 · Cited by 50

In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma

Knudsen, N. H., Escobar, G., Korell, F., Kienka, T., Nobrega, C., Anderson, S., Cheng, A. Y., Zschummel, M., Armstrong, A., Bouffard, A. A., et al. (2025) · Nature · doi:10.1038/s41586-025-09489-8 · Cited by 51

Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression

Alishvandi, A., Aram, C., Shahrivar, F. F., Kesharwani, P., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02506-4 · Cited by 55

Intracellular delivery of colloids: Past and future contributions from microinjection

Tiefenboeck, P., Kim, J. A., & Leroux, J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.013 · Cited by 47

Surgery-free injectable macroscale biomaterials for local cancer immunotherapy

Lei, K., & Tang, L. (2018) · Biomaterials Science · doi:10.1039/c8bm01470a · Cited by 46

Emerging Immunotherapies in the Treatment of Brain Metastases

Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2020) · The Oncologist · doi:10.1002/onco.13575 · Cited by 48

Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy

Marofi, F., Rahman, H. S., Thangavelu, L. P., Dorofeev, A. E., Bayas-Morejón, F., Shirafkan, N., Shomali, N., Chartrand, M. S., Jarahian, M., Vahedi, G., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02251-7 · Cited by 47

Impact of immune cells on the hallmarks of cancer: A literature review

Costa, A. C., Santos, J., da Costa, R. M. G., & Medeiros, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103541 · Cited by 48

Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks

Jaeger-Ruckstuhl, C. A., Lo, Y., Fulton, E. C., Waltner, O. G., Shabaneh, T. B., Simon, S., Muthuraman, P. V., Correnti, C., Newsom, O. J., Engström, I., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.011 · Cited by 49

Transmembrane domain–driven PD-1 dimers mediate T cell inhibition

Philips, E. A., Liu, J., Kvalvaag, A. S., Mørch, A. M., Tocheva, A. S., Ng, C., Liang, H., Ahearn, I. M., Pan, R., Luo, C. C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade6256 · Cited by 46

Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits

Frankel, N. W., Deng, H., Yucel, G., Gainer, M., Leemans, N., Lam, A., Li, Y., Hung, M. E., Lee, D., Lee, C.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114145 · Cited by 49

Cell-based immunotherapy approaches for multiple myeloma

Kriegsmann, K., Kriegsmann, M., Cremer, M., Schmitt, M. W., Dreger, P., Goldschmidt, H., Müller‐Tidow, C., & Hundemer, M. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0346-9 · Cited by 46

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 33

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 182

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01